AJCC 8^(th)解剖学及预后分期系统用于TNBC生存获益价值评估

Clinical Value of AJCC8^(th) Anatomical and Prognostic Staging System in Survival Benefit Evaluation of TNBC

目的探讨AJCC 8^(th)解剖学及预后分期系统用于三阴性乳腺癌(triple negative breast cancer,TNBC)生存获益的价值评估。方法回顾性分析我院2010年1月至2015年12月收治的147例TNBC患者的临床资料,比较不同解剖学及预后分期生存获益情况,评价AJCC 8^(th)解剖学和预后分期的差异。结果入选患者随访5年无进展生存(progression free survival,PFS)率和总生存(overall survival,OS)率分别为84.72%和84%;不同解剖学分期患者PFS率(除外Ⅳ期)和OS率比较差异有统计学意义(P<0.05);不同预后分期患者PFS率和OS率比较差异有统计学意义(P<0.05);147例患者中AJCC 8^(th)解剖学和预后分期变化者共135例(91.84%),与解剖学分期相比预后分期均提高;AJCC 8^(th)预后分期较解剖分期升高的患者各组PFS率和OS率比较差异有统计学意义(P<0.05)。结论AJCC 8^(th)预后分期系统用于TNBC预后评估可有效补充解剖学分期的不足,为临床决策的制定提供更多参考。

Objective To investigate the clinical value of AJCC 8^(th)anatomical and prognostic staging system in evaluating survival benefit of triple negative breast cancer(TNBC).Methods The clinical data of 147 TNBC patients admitted from January 2010 to December 2015 were enrolled and analyzed retrospectively.The survival benefits of different anatomic and prognostic stages were compared,and the differences in AJCC 8^(th)anatomical and prognostic stages were evaluated.Results The PFS rate and OS rate in 5-year of all patients were 84.72%and 84%respectively.There were significant differences in PFS rate(except stageⅣ)and OS rate among the patients with different anatomical stages(P<0.05).There were remarkable significant differences in PFS rate and OS rate among the patients with different prognosis stages(P<0.05).135(91.84%)out of 147 cases were found the staging changes in anatomy and prognosis stage of AJCC 8^(th),which were higher than anatomical stage.In the patients with rising AJCC 8th prognostic stage,there was significant difference in PFS rate and OS rate among the different groups(P<0.05).Conclusion AJCC 8^(th)prognostic staging system can effectively supplement the disadvantage of anatomical staging for prognosis evaluation of TNBC,and provide more reference for clinical decision-making.